CY1118886T1 - Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης - Google Patents
Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινηςInfo
- Publication number
- CY1118886T1 CY1118886T1 CY20171100501T CY171100501T CY1118886T1 CY 1118886 T1 CY1118886 T1 CY 1118886T1 CY 20171100501 T CY20171100501 T CY 20171100501T CY 171100501 T CY171100501 T CY 171100501T CY 1118886 T1 CY1118886 T1 CY 1118886T1
- Authority
- CY
- Cyprus
- Prior art keywords
- phenylsulfanyl
- piperazine
- dimethyl
- phenyl
- therapeutic uses
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37588510P | 2010-08-23 | 2010-08-23 | |
| DKPA201000739 | 2010-08-23 | ||
| PCT/DK2011/050317 WO2012025123A1 (en) | 2010-08-23 | 2011-08-22 | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118886T1 true CY1118886T1 (el) | 2018-01-10 |
Family
ID=44532506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100501T CY1118886T1 (el) | 2010-08-23 | 2017-05-10 | Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης |
Country Status (32)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA029060B1 (ru) | 2014-01-31 | 2018-02-28 | Эгиш Дьёдьсердьяр Зрт. | Способ получения солей вортиоксетина |
| CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
| CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
| CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
| MA45532A (fr) | 2016-07-01 | 2019-05-08 | H Lundbeck As | Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8430581D0 (en) * | 1984-12-04 | 1985-01-09 | Ferrosan As | Treatment |
| ES2087463T3 (es) * | 1991-11-18 | 1996-07-16 | Lilly Industries Ltd | Benzo(b)tiofen-2-carboxamidas para el tratamiento de trastornos del sistema nervioso central. |
| US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| WO2002029232A1 (en) | 2000-10-02 | 2002-04-11 | Rohr, Inc. | Apparatus, method and system for gas turbine engine noise reduction |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| MY150647A (en) * | 2006-06-16 | 2014-02-14 | Lundbeck & Co As H | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment |
| TW200848411A (en) | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
-
2011
- 2011-08-17 TW TW100129338A patent/TW201212918A/zh unknown
- 2011-08-19 AR ARP110103029A patent/AR082501A1/es not_active Application Discontinuation
- 2011-08-22 CN CN2011800406861A patent/CN103068389A/zh active Pending
- 2011-08-22 US US13/812,073 patent/US20130184291A1/en not_active Abandoned
- 2011-08-22 IL IL224371A patent/IL224371A/en active IP Right Grant
- 2011-08-22 LT LTEP11749331.2T patent/LT2608789T/lt unknown
- 2011-08-22 BR BR122020025600A patent/BR122020025600A2/pt not_active Application Discontinuation
- 2011-08-22 AP AP2013006768A patent/AP3583A/xx active
- 2011-08-22 RU RU2013112890/15A patent/RU2564666C2/ru active
- 2011-08-22 ES ES11749331T patent/ES2625142T5/es active Active
- 2011-08-22 HR HRP20170608TT patent/HRP20170608T4/hr unknown
- 2011-08-22 JP JP2013525143A patent/JP5902169B2/ja active Active
- 2011-08-22 KR KR1020137004481A patent/KR101816953B1/ko active Active
- 2011-08-22 PL PL11749331.2T patent/PL2608789T5/pl unknown
- 2011-08-22 BR BR112013002194A patent/BR112013002194A2/pt not_active Application Discontinuation
- 2011-08-22 MX MX2013001570A patent/MX349724B/es active IP Right Grant
- 2011-08-22 ME MEP-2017-94A patent/ME02674B/me unknown
- 2011-08-22 SM SM20170239T patent/SMT201700239T1/it unknown
- 2011-08-22 FI FIEP11749331.2T patent/FI2608789T4/fi active
- 2011-08-22 SG SG2013007380A patent/SG187649A1/en unknown
- 2011-08-22 PT PT117493312T patent/PT2608789T/pt unknown
- 2011-08-22 CA CA2807062A patent/CA2807062C/en active Active
- 2011-08-22 DK DK11749331.2T patent/DK2608789T4/da active
- 2011-08-22 SI SI201131177T patent/SI2608789T2/sl unknown
- 2011-08-22 RS RS20170404A patent/RS55851B2/sr unknown
- 2011-08-22 AU AU2011295465A patent/AU2011295465B8/en active Active
- 2011-08-22 HU HUE11749331A patent/HUE034155T2/en unknown
- 2011-08-22 WO PCT/DK2011/050317 patent/WO2012025123A1/en not_active Ceased
- 2011-08-22 EP EP11749331.2A patent/EP2608789B2/en active Active
-
2013
- 2013-02-20 CL CL2013000492A patent/CL2013000492A1/es unknown
- 2013-02-21 CO CO13035030A patent/CO6680652A2/es unknown
- 2013-02-22 ZA ZA2013/01385A patent/ZA201301385B/en unknown
-
2017
- 2017-05-10 CY CY20171100501T patent/CY1118886T1/el unknown
-
2018
- 2018-09-07 US US16/124,497 patent/US20190000836A1/en not_active Abandoned
-
2020
- 2020-05-18 US US16/877,108 patent/US20210085674A1/en not_active Abandoned
-
2022
- 2022-01-07 US US17/570,998 patent/US20220370439A1/en not_active Abandoned
-
2023
- 2023-10-10 US US18/483,780 patent/US20240293397A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2025013I1 (el) | Αρυλικες, ετεροαρυλικες και ετεροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση διαταραχων που διαμεσολαβουνται απο το συμπληρωμα | |
| CY1117978T1 (el) | Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a | |
| AR122051A2 (es) | Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina | |
| CY1125550T1 (el) | Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων | |
| CY1120318T1 (el) | Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων | |
| UY34161A (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen | |
| CY1117615T1 (el) | Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης | |
| CY1117424T1 (el) | Βενζοδιαζεπινικος αναστολεας bromodomain | |
| UA110103C2 (uk) | Модифікований туберкульозний антиген | |
| CL2014001765A1 (es) | Proceso para la fabricacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina. | |
| CY1117527T1 (el) | Συνθεσεις και χρησεις για θεραπευτικη αγωγη πνευμονικης κυψελιδικης πρωτεϊνωσης | |
| CY1110026T1 (el) | Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων | |
| UY32649A (es) | "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato" | |
| CY1121421T1 (el) | Φαρμακοτεχνικες μορφες | |
| CY1117105T1 (el) | Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao | |
| GB201209587D0 (en) | Therapeutic compounds | |
| CL2011000481S1 (es) | Aplicador para cuidado oral. | |
| UY34775A (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple | |
| CY1123766T1 (el) | Trans-4-{2-[4-(2,3- διχλωροφαινυλ)-πιπepazin-1-yλ]-aiθyλ}- ν,ν-διμεθυλκαρβαμοϋλ-κυκλοεξυλαμινη για θεραπεια πρωταρχικων αρνητικων συμπτωματων σχιζοφρενειας | |
| CY1118371T1 (el) | Αναστολεις του iap | |
| CY1120133T1 (el) | Πυριδαζινονες ως αναστολεις ενζυμου daao | |
| BR112013002194A2 (pt) | uso de 1-[2-(2,4-dimetil-fenilsulfanil)fenil] piperazina e seus sais farmaceuticamente aceitáveis | |
| MX2010010876A (es) | Piperidinas sustituidas como compuestos terapeuticos. | |
| CY1118117T1 (el) | Νεα αμινο-πυρρολινικα παραγωγα και η χρηση τους στην προληψη ή και τη θεραπεια του μεταβολικου συνδρομου | |
| CY1116334T1 (el) | Νεο πολυμορφο |